Trials / Active Not Recruiting
Active Not RecruitingNCT05784441
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-90009530 | JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20 |
Timeline
- Start date
- 2023-11-06
- Primary completion
- 2027-01-06
- Completion
- 2040-01-03
- First posted
- 2023-03-24
- Last updated
- 2026-04-13
Locations
15 sites across 4 countries: United States, Australia, Israel, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05784441. Inclusion in this directory is not an endorsement.